MX375474B - Composición médica que contiene un inhibidor para absorción de colesterol y un inhibidor para la biosíntesis de colesterol. - Google Patents
Composición médica que contiene un inhibidor para absorción de colesterol y un inhibidor para la biosíntesis de colesterol.Info
- Publication number
- MX375474B MX375474B MX2016004021A MX2016004021A MX375474B MX 375474 B MX375474 B MX 375474B MX 2016004021 A MX2016004021 A MX 2016004021A MX 2016004021 A MX2016004021 A MX 2016004021A MX 375474 B MX375474 B MX 375474B
- Authority
- MX
- Mexico
- Prior art keywords
- composition containing
- inhibitor
- cholesterol
- interaction
- active ingredient
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 4
- 230000003993 interaction Effects 0.000 abstract 3
- 239000012071 phase Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000007790 solid phase Substances 0.000 abstract 2
- 230000006835 compression Effects 0.000 abstract 1
- 238000007906 compression Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940074795 rosuvastatin and ezetimibe Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona con una composición farmacéutica que contiene rosuvastatina y ezetimibe, en donde se reduce al mínimo la interacción del ingrediente activo y un excipiente, los ingredientes activos están presentes en fases separadas espacialmente o en contacto físico y en donde la liberación del ingrediente activo a partir de las dos fases se lleva a cabo de forma separada temporalmente en lugar de presentarse al mismo tiempo o inicia con retraso desde una fase en comparación con la otra, distinta. Un aspecto adicional de la presente invención es un método para disminuir una interacción del ingrediente activo-excipiente o una interacción entre los ingredientes activos en una composición farmacéutica combinada que contienen diversas fases sólidas producidas mediante compresión, la cual comprende ajustar el tiempo de desintegración de las diferentes fases solidas comprimidas unas de otras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1300564A HU231036B1 (hu) | 2013-09-30 | 2013-09-30 | Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény |
| PCT/HU2014/000089 WO2015044698A2 (en) | 2013-09-30 | 2014-09-30 | Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004021A MX2016004021A (es) | 2016-09-06 |
| MX375474B true MX375474B (es) | 2025-03-06 |
Family
ID=89991271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004021A MX375474B (es) | 2013-09-30 | 2014-09-30 | Composición médica que contiene un inhibidor para absorción de colesterol y un inhibidor para la biosíntesis de colesterol. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3052088A2 (es) |
| CN (2) | CN114796148A (es) |
| BR (1) | BR112016006888A2 (es) |
| EA (1) | EA034711B1 (es) |
| HU (1) | HU231036B1 (es) |
| MX (1) | MX375474B (es) |
| UA (1) | UA120167C2 (es) |
| WO (1) | WO2015044698A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3243506A1 (en) | 2016-05-09 | 2017-11-15 | Adamed sp. z o.o. | Pharmaceutical composition |
| JP2017210455A (ja) * | 2016-05-27 | 2017-11-30 | ニプロ株式会社 | エゼチミブ含有医薬組成物 |
| CZ2016538A3 (cs) | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky |
| CZ2016539A3 (cs) * | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy |
| WO2021019499A1 (en) | 2019-07-31 | 2021-02-04 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Solid oral multiple-unit immediate release compositions, methods and uses thereof |
| GR1010183B (el) * | 2020-12-14 | 2022-03-01 | Elpen Αε Φαρμακευτικη Βιομηχανια, | Στερεες φαρμακοτεχνικες μορφες ατορβαστατινης και εζετιμιμπης |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006134604A1 (en) * | 2005-06-15 | 2006-12-21 | Hetero Drugs Limited | Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| JP5467870B2 (ja) * | 2007-02-09 | 2014-04-09 | アルファファーム ピーティーワイ リミテッド | 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態 |
| WO2009024889A2 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| EP2204170A1 (en) * | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
| EP2448919A2 (en) * | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
| EP2483248B1 (en) * | 2009-07-24 | 2016-07-20 | Egis Gyógyszergyár Zrt. | Crystalline form i rosuvastatin zinc salt |
| US8927021B2 (en) * | 2009-07-28 | 2015-01-06 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszventarsasag | Granulating process and thus prepared granulate |
| CN102357096A (zh) * | 2011-09-09 | 2012-02-22 | 北京阜康仁生物制药科技有限公司 | 一种含有他汀类药物锌盐的降血脂组合物 |
| EP2844233B1 (en) * | 2012-05-01 | 2020-05-06 | Althera Life Sciences, LLC | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
| MX2012014970A (es) * | 2012-12-18 | 2013-08-27 | Hetlabs Mexico S A De C V | Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso. |
-
2013
- 2013-09-30 HU HU1300564A patent/HU231036B1/hu unknown
-
2014
- 2014-09-30 EP EP14800125.8A patent/EP3052088A2/en active Pending
- 2014-09-30 CN CN202111466045.4A patent/CN114796148A/zh active Pending
- 2014-09-30 BR BR112016006888A patent/BR112016006888A2/pt not_active Application Discontinuation
- 2014-09-30 CN CN201480061593.0A patent/CN105722505A/zh active Pending
- 2014-09-30 WO PCT/HU2014/000089 patent/WO2015044698A2/en not_active Ceased
- 2014-09-30 EA EA201690666A patent/EA034711B1/ru active IP Right Revival
- 2014-09-30 UA UAA201603734A patent/UA120167C2/uk unknown
- 2014-09-30 MX MX2016004021A patent/MX375474B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3052088A2 (en) | 2016-08-10 |
| WO2015044698A3 (en) | 2015-05-14 |
| UA120167C2 (uk) | 2019-10-25 |
| EA034711B1 (ru) | 2020-03-12 |
| CN114796148A (zh) | 2022-07-29 |
| HU231036B1 (hu) | 2019-12-30 |
| HUP1300564A2 (en) | 2015-04-28 |
| MX2016004021A (es) | 2016-09-06 |
| BR112016006888A2 (pt) | 2017-08-01 |
| EA201690666A1 (ru) | 2016-08-31 |
| WO2015044698A2 (en) | 2015-04-02 |
| CN105722505A (zh) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015044698A3 (en) | Medical composition containing a cholesterol absorption inhibitor and cholesterol biosynthesis inhibitor | |
| MY198246A (en) | Novel Ferroportin Inhibitors | |
| WO2015031564A3 (en) | Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors | |
| MY185500A (en) | Macrocylic pyridine derivatives | |
| MY185491A (en) | Macrocylic pyrimidine derivatives | |
| EP3308785A3 (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| AU2012347200A8 (en) | Tablet capable of combatting misuse by injection | |
| WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
| MX2020012989A (es) | Agente terapeutico para la fibrosis. | |
| MX363699B (es) | Producto de comicronizacion que comprende acetato de ulipristal. | |
| WO2010147440A3 (ko) | 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물 | |
| PH12017501397A1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2014014579A (es) | Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide. | |
| MX370342B (es) | Preparaciones solidas que contienen tofogliflozina y proceso para producir las mismas. | |
| PH12015500395A1 (en) | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor | |
| EP3031465A4 (en) | Pharmaceutical composition for promoting bone tissue formation, containing stauntonia hexaphylla leaf extract as active ingredient | |
| MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
| UA105285C2 (uk) | Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання | |
| WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
| MX2017008076A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß. | |
| MX2013015272A (es) | Cristales micronizados. | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| WO2014021591A3 (ko) | 신규한 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GD | Licence granted |